Combining Lovastatin and a Parent-Implemented Language Intervention in a Multimodal Treatment for Fragile X Syndrome
Phase: PHASE4
Conditions: Fragile X Syndrome, Genetic Diseases
Sponsor: University of California, Davis

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 1 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
1) Protocol Title: Combining Lovastatin and a Parent-Implemented Language 
Intervention in a Multi-Modal Treatment of Fragile X Syndrome 
 
2) Author of Protocol 
X UC Davis Researcher 
 Researcher from other institution 
 Private Sponsor 
 Cooperative Group 
 Other:   
 
 
3) Objectives 
Aim 1. Test the efficacy of a 20 week multi-modal treatment comprised of lovastatin 
and the Parent-implemented Language Intervention (PILI) for children with FXS. 
Children will be randomized to drug or placebo in a double-blind design with all 
participating in the PILI. The primary endpoint will be a spoken language composite 
and the secondary endpoint will be challenging behavior. We will test the following 
hypotheses: 
Hypothesis 1a. Improvements in spoken language and behavior will be 
greater among lovastatin-treated than placebo treated participants. 
Hypothesis 1b. Improvements in parental use of the PILI-targeted strategies 
will be associated with greater improvements in child language and 
behavior, especially in the lovastatin-treated group, thereby demonstrating 
benefit of the combined intervention. 
Aim 2. (a) Identify biomarkers in peripheral immune cells associated with FXS and 
the efficacy of treatment and (b) elucidate the cellular/molecular mechanisms by 
which lovastatin influences MEK/ERK and Rho GTPase signaling pathways and 
immunological abnormalities associated with FXS. 
Hypothesis 2a. Lovastatin corrects core biochemical and physiological 
impairments by normalizing Ca2+dependent and/or Ca2+-independent 
regulation of the MEK/ERK signaling pathway. 
Hypothesis 2b. Lovastatin normalization of MEK/ERK signaling and/or Rho 
GTPase signaling is mediated by its effects on isoprenoid synthesis. 
Hypothesis 2c. Individuals with elevated inflammatory cytokines will be 
more responsive to lovastatin. 
4) Background 
This is the first multi-modal treatment to combine a targeted treatment for FXS, 
lovastatin, with an innovative parent-implemented intervention (PILI) targeting 
language and challenging behavior delivered through telehealth technology. Our 
hypothesis is that targeted treatments will be more effective when applied in 
combination with PILI. We also will examine whether changes in the activity of key 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 2 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
pathways/proteins influenced by FMRP (the mitogen-activated protein kinase (ERK) 
and MMP-9) are biomarkers of treatment responsiveness. Because lovastatin is also 
an anti-inflammatory, we will characterize MEK/ERK signaling in peripheral 
immune cells both and pre- and post- treatment to determine whether levels of these 
signaling molecules are predictive biomarkers of treatment response. We 
hypothesize that those individuals with elevated inflammatory cytokine profiles will 
be most responsive to lovastatin treatment. Once modeled in FXS, results from these 
studies can then be applied to other neurodevelopmental disorders including 
Rasopathies. 
Lovastatin as a treatment for FXS: Lovastatin is an inhibitor of the rate-limiting 
enzyme in cholesterol biosynthesis and an FDA-approved treatment for 
hyperlipidemia. Lovastatin has also been proposed as a treatment for IDD, 
particularly for Rasopathies and Neurofibromatosis Type 1 (NF1). Lovastatin 
reduces activation of the small guanosine triphophatase (GTPase) Ras, which in turn 
reduces activity of the MEK/ERK signaling pathway. Lovastatin interferes with 
recruitment of Ras to the membrane, a process required to transition from inactive 
GDP to active GTP. The interaction of Ras with the membrane requires the prost-
translational addition of a farnesyl group to the C terminus of Ras, and lovastatin 
inhibits Ras farnesylation by targeting the upstream mevalonate pathway. 
Recent extensions of animal studies to FXS have been promising. In a study of Fmr1 
knock out (KO) mouse, intraperitoneal injections of lovastatin protected the mice 
from audiogenic seizures that are part of the FXS phenotype. In the KO mouse, the 
lack of FMRP represents a loss of the translational repressor for many proteins 
important for synaptic plasticity. Lovastatin corrected the excessive protein 
production in the KO mouse, inhibited RAS-ERK1/2 signaling in hippocampal 
neurons, and improved the phenotype. Although lovastatin has been used to treat 
children as young as one year of age, FDA approval extends only to 10- to 17-years-
olds and studies of efficacy for cognitive impairments in NF1 have shown benefit 
and safety for this age range so this study will focus on the same age group. 
Parent-implemented Intervention (PILI) for FXS: McDuffie, Abbeduto, and 
colleagues have developed an intervention to teach parents how to interact with their 
children with IDD, including those with FXS, in ways that optimize language 
learning. The intervention integrates, in novel ways, several intervention principles 
with a well- documented evidence base (see grant for efficacy articles). 
The PILI consists of didactic parent education sessions paired with real-time clinician 
coaching of parent-child interactions. Both types of sessions are aimed at enhancing 
parental verbal responsiveness (PVR). PVR is an interactional style characterized by 
talking about the child’s focus of attention, exposing the child to diverse vocabulary 
and elaborated sentence structure, creating frequent opportunities for the child to 
communicate, and providing affectively positive and contingent verbal responses to 
child utterances. The broad goal of PVR is to expose the child to increased amounts 
of verbal language input slightly in advance of his/her current level of competence 
while providing numerous opportunities to use newly acquired language. 
 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 3 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
Numerous longitudinal studies have shown that increased PVR is associated with 
more positive language outcomes for typically and atypically developing children 
(e.g., Siller & Sigman, 2002), including those with FXS (Warren, et al., 2010). The 
PILI also facilitates parental use of PVR strategies in a broad range of naturally 
occurring interactions with the child (e.g., dinner time) outside of the intervention 
context. In essence, PILI turns the parent into “the agent of change” for the child – a 
role traditionally assumed by the speech-language clinician working directly with the 
child. Making the parent the agent of change can expose the child to a higher rate of 
language learning opportunities compared to a traditional clinician-implemented 
intervention, thereby making PILI highly cost effective (Ingersoll & Gergans, 2007). 
Many parents find it difficult to engage in verbally responsive interactions with FXS 
because of the challenging behaviors displayed by children with FXS (Abbeduto et 
al., 2004). Put simply, being verbally responsive is not an option if a child is having a 
tantrum, refusing to engage in interaction, or has a narrow range of interests and 
preferred activities. In the case of FXS, the phenotype includes numerous challenging 
behaviors and comorbid conditions, including social anxiety (Cordiero et al., 2012), 
inattention (Cornish et al., 2004), hyperarousal (Belser & Sudhalter, 2001), 
symptoms of autism (McDuffie et al., 2010), repetitive behaviors (Hall et al., 2010), 
self-injury (Symons et al., 2003), and aggression (Leigh et al., 2012). Although the 
physiology of FXS contributes to these behaviors, environmental contingencies help 
maintain these behaviors and so, parents can be taught to prevent or reduce 
challenging child behaviors by modifying social-environmental antecedents and 
consequences or teaching more adaptive “replacement” behaviors (Hall et al.,2006; 
Koegel et al., 1996; Moskowitz, 2011). In the PILI, therefore, individualized 
strategies for addressing challenging behaviors are provided during parent education 
sessions and parent use of these strategies is encouraged during coaching sessions. 
The PILI of McDuffie and colleagues has been delivered largely through video 
teleconferencing (VTC) technology, an approach that has both practical and 
theoretical advantages. Extensive clinic-based instruction would create an unrealistic 
travel burden for families. Additionally, enhancing PVR in the home has the 
advantage of facilitating generalization of child gains in spoken language that often 
do not transfer from the clinic to real world settings (Dunst & Kassow, 2008). 
Delivery of health care via VTC is increasingly common (Ekeland, Bowes, & 
Flottorp, 2010), and a growing body of research supports the use of VTC to deliver 
interventions to children with IDD as well as coaching to teachers, therapists, and 
parents (Machalicek et al., 2010, 2009a, 2009b). McDuffie, Abbeduto, and 
colleagues recently completed two studies examining the use of VTC to deliver 
parent-implemented language intervention in the home to mothers of young children 
with either ASD (McDuffie et al., 2013) or FXS (Oakes et al., 2013). In both studies, 
PVR increased equally in coaching sessions conducted in the clinic and in the family 
home using VTC, and parents expressed a strong preference for more VTC relative 
to in-clinic sessions. 
The initial trials of the PILI focused on 2- to 5-year-olds. There are virtually no 
evidence- based language/behavior interventions for older children and adolescents 
with FXS. Nevertheless, there is evidence that PVR continues to be important for 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 4 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
children with FXS well into adolescence (Brady et al., in preparation), although the 
linguistic content to be acquired is different for older individuals. In the present 
project, we adapt the PILI for 10- to 17-year-olds with FXS and their 
parents/caregivers by embedding the intervention in narrative activities. 
Narrative as a Context for Intervention: In working with parents of 2- to 5-year-olds 
in PILI, McDuffie and colleagues taught them within the context of object-based 
play and caretaking routines (e.g., getting the child dressed) because these activities 
occupy a large proportion of their naturally occurring interactions. These interactive 
contexts are less central in the lives of older children and adolescents with FXS and 
their parents/caregivers. In the present project, we propose to focus on the context of 
joint story-telling, or narrative, activities. Children use narrative to organize and 
make sense of the world (Bruner, 1985). Joint book-reading is one of the earliest 
forms of narrative to which children are exposed and it remains an important context 
for acquiring and practicing language skills into adolescence. Moreover, there is 
substantial empirical support for the efficacy of embedding language intervention 
targeted into narrative interactions for older children and adolescents. Narrative based 
language interventions are structured around the context of a shared story-telling 
activity based on a book with illustrations. This type of intervention is well-suited to 
involving the parent/caregiver as interventionist because time spent in shared story-
telling not only predicts later language outcomes but represents a routine activity, 
parents/caregivers can be verbally responsive by modeling more advanced vocabulary 
and grammar, by asking open-ended questions that prompt the child to use more 
advanced language, and by responding contingently to child utterances with indirect 
corrective feedback. The story content provides the topic of the conversational 
interaction while the illustrations in the book encourage child engagement, support 
comprehension of the shared topic, and provide visual support for child responses. 
In summary, the behavioral component of the proposed multi-modal treatment will be 
a PILI that targets improvements in spoken language and challenging behavior for 
10- to 17-year-olds with FXS by increasing PVR within picture-book based story-
telling episodes. Finally, parents/caregivers will be encouraged to use the targeted 
strategies in other everyday interactions with their child. The intervention will be 
delivered to parents/caregivers in their homes by way of VTC. Considerable 
preliminary work will need to be conducted, however, before combining it with 
lovastatin. Thus, we propose to spend the first 18 months of the project conducting 
two small-scale studies of PILI alone. The first phase (Phase 1) of the PILI study was 
designed to collect preliminary data, enrolled three mothers and their sons and will 
be completed by end of December 2014. NIH has requested that we continue to test 
the preliminary efficacy of the behavioral intervention using a small N group design 
study prior to implementing the phase of the intervention which includes the drug 
Thus, the second phase of the study (Phase 2) will be a group design (N=30) with 
randomized assignment to a Treatment Group or a Wait List Comparison Group. 
Participants in the Treatment Group receive the behavioral intervention and the Wait 
List Comparison Group receives treatment as usual. The final phase of the study 
(Phase3) will be a clinical trial (N=50) in which participants are randomly assigned 
to receive the behavioral intervention alone or in combination with Lovastatin. 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 5 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
5) Inclusion and Exclusion Criteria 
Subjects will be screened initially through a pre-screening form either over the phone 
or in person at the MIND Institute. If the subject is eligible based on the responses to 
the pre-screening form they will be given the option of scheduling a screening visit to 
complete screening assessments and confirm if language level and overall functioning 
are adequate to participate in the trial. 
Inclusion Criteria: 
1. Documentation of a full mutation with absence or deficient FMRP levels. 
2. Males and females ages 10 through 17 years (Consent Forms A and B). 
Note: 
a. Pilot participants who are recruited for a one-time session using 
Consent Form C, will be between 6 and 23years of age with a 
diagnosis of Fragile X Syndrome or Down Syndrome. This will allow 
the researchers to obtain pilot participants from an available pool of 
participants who are visiting Dr. Abbeduto’s lab to take part in other 
studies of language development in FXS. 
b. An additional cohort of three participants will be recruited using 
Consent Form D. These participants will be between the ages of 5 and 
8 years old which will constitute a downward extension of the current 
project, allowing us to test the feasibility of PILI in a younger 
population. Participants using Consent Form D will not participate in 
the clinical trial combining the behavioral intervention plus lovastatin. 
3. Willingness of potential study participant as well as a parent or caretaker to 
participate in the protocol. 
4. Speech is the primary means of communication with three-word or longer 
utterances used on a daily basis. 
5. IQ ≤70 as measured by the Leiter- R. 
6. Sexually active women of childbearing potential (WCBP) must be using a 
medically acceptable method of birth control and have a negative qualitative 
serum β-human chorionic growth hormone (β-HCG) or urine pregnancy 
test collected at the initial screening visit. A woman of childbearing 
potential is defined as a female who is biologically capable of becoming 
pregnant. A medically acceptable method of birth control includes 
intrauterine devices in place for at least 3 months, surgical sterilization, or 
adequate barrier methods (e.g., diaphragm and foam). An oral 
contraceptive alone is not considered adequate for the purpose of this study. 
Use of oral contraceptives in combination with another method (e.g., a 
spermicidal cream) is acceptable. In subjects who are not sexually active, 
abstinence is an acceptable form of birth control and serum βHCG or urine 
will be tested. 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 6 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
Exclusion Criteria: 
1. Persons who do not speak English. 
The following exclusion criteria apply only to the clinical trial phase of the 
study (Phase 3 corresponding to Consent Form B). 
2. Changes in any medications (including investigational medications) within 
the last month (4 weeks). All concomitant medications must have been on a 
stable course for at least 4 weeks prior to enrollment into the study and 
maintain stability throughout the course of the study. 
3. Changes in behavioral therapy or educational programming during the 
study. This does not include scheduled school holidays. 
4. Have any disease or condition (medical or surgical) at screening that might 
compromise the hematologic, cardiovascular, pulmonary, renal, 
gastrointestinal, or hepatic systems; or other conditions that might interfere 
with the absorption, distribution, metabolism, or excretion of the 
investigational product, or would place the subject at increased risk. 
5. Patients who, in the opinion of the investigator, are unsuitable in any other 
way to participate in this study, including being unable to comply with the 
requirements of the study or displaying clinically significant abnormalities 
in safety assessments at screening. 
6. Patients on prohibited medications (see package insert for more 
information): 
a. Potent inhibitors of CYP3A4 (itraconazole, ketoconazole, 
posaconazole, voriconazole, HIV protease inhibitors, boceprevir, 
telaprevir, erythromycin, clarithromycin, telithromycin, and 
nefazodone) 
b. Gemfibrozil 
c. Other lipid-lowering drugs 
d. Cyclosporine 
e. Danazol, diltiazem, dronedarone, or verapamil 
f. Amiodarone 
g. Colchicine 
h. Ranolazine 
i. Coumarin anticoagulants 
j. mGluR5 antagonists 
7. History of recurrent status epilepticus. 
8. Inability to withhold grapefruit and grapefruit juice from diet during the 
entire clinical trial. 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 7 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
9. Subjects unwilling to abstain from alcoholic beverages during the trial 
10. Subjects who are actively suicidal. 
6) Number of Subjects 
We hope to enroll up to 113 participants through the entire study under the 4 consent 
form versions. Consent form A will be utilized to enroll up to 30 subjects and their 
mothers. Consent form B will be utilized to enroll up to 50 subjects and their 
mothers/caregivers into the clinical trial portion of the study. Up to 30 additional pilot 
participants may be recruited from ongoing studies here at the MIND using Consent 
form C. Mothers of the pilot participants enrolled under consent form C will not be 
involved in the clinician-child interactions. We will also recruit 3 boys with FXS 
between the ages of 5- and 8-years old to participate in a downward extension of the 
study utilizing Consent form D. This brings the total number of potential participants 
to 113. 
7) Recruitment Methods 
Initially, subjects will be recruited from the Sacramento, California metropolitan area 
and once local FXS populations have been exhausted, recruitment will extend 
nationwide to families who are capable of traveling to and from the MIND Institute to 
complete all necessary assessments. Patients from investigators’ practices and those 
referred will also be eligible to participate, and may be recruited. If a physician 
believes his or her patient may be a good candidate for this study and the family 
agrees to be contacted or has approved being contacted for future research 
opportunities (a component of most consent forms in FXS studies), the physician will 
notify the study coordinator who will offer the family a flyer and may contact the 
family to do a prescreening form. If the patient appears to be a good candidate based 
on the prescreening form, they will be scheduled for a screening visit. 
Participants will also be recruited using a short recruitment statement which will be 
posted on the list serve of the National Fragile X Foundation and other list serves or 
social media associated with FXS or neurodevelopmental disorders. Recruitment 
flyers, brochures, and posters may be placed around UCDHS facilities or 
disseminated at conferences or recruitment events associated with 
neurodevelopmental disorders. 
We are requesting a HIPAA waiver for recruitment purposes only. The research team 
will identify potential subjects and access medical records to verify eligibility prior 
to the treating physician and research coordinator approaching the potential subject. 
Consent to participate and HIPAA Authorization to access additional information in 
the medical records will be obtained prior to enrollment into the study. The protected 
health information will not be reused or disclosed to outside persons or entities. 
The review of subjects' medical records is for limited information and only to 
determine eligibility. The data are derived from clinically indicated procedures and 
there is minimal risk to the subjects' status, employment, or insurability. Only 
research personnel will access medical records via EMR, and all personnel are 
required to use the “Quick Disclosure” function in EMR to document review. 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 8 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
Without an initial review of the medical record for screening purposes, it would not 
be possible to identify potential subjects and confirm their applicability for study 
participation. 
Once eligibility is confirmed, subjects will be approached to obtain their 
authorization to access and use their health information for the research. Please see 
Section 14 for additional information regarding Data Management and 
Confidentiality. 
8) Compensation to the Subjects 
Subjects will not be compensated for their participation. Possible expenses to the 
subject’s family include time spent at the clinic as well as expenses for travelling. 
Therefore subjects who would otherwise not be able to participate may be eligible for 
travel reimbursement for travel costs incurred as specified in question 25. 
9) 
Study Timelines 
We anticipate seeing 30 pilot participants in the first 18 months under consent form C. 
During this same time period up to an additional thirty participants and their mothers 
will be seen under consent form A, phases 1 and 2 of the study. During Phase 3, 50 
participants and their parent/caregiver will be recruited into the clinical trial portion 
utilizing consent form B. In addition, 3 subjects will be recruited into phase 4, under 
consent form D. Phases 2,3, and 4 of the study, using consent forms A, B and D, will 
occur over the last 3.5 years of the project). 
10) Study Endpoints 
The primary outcome measure is a spoken language composite measured at baseline 
and at the end of treatment. Comparison of the two treatment groups on the outcome 
measure will be made through analysis of covariance, adjusted for baseline values on 
that measure using an intent-to-treat approach. Two-sided tests will be used with 
alpha at .05. With this sample size, power to detect a moderate effect size of 0.6 will 
be 80%, assuming equal standard deviations in the groups. The assumptions we are 
making to estimate power are conservative as evidenced by recent published tests of 
a parent mediated intervention for autism (Rogers et al., 2012) and a randomized 
controlled trial of a drug in FXS (Berry-Kravis et al., 2012), with samples sizes of 98 
and 60, respectively, and behavioral outcome measures. 
Analysis of our secondary outcome measure, the social avoidance subscale of the 
FXS- normed ABC, as well as the exploratory VAS and CGI will follow the same 
approach as the primary analysis. Additional analyses will examine potential child 
moderators of response to lovastatin (age, Leiter, ADOS symptom severity) using 
linear regression. 
Aim 1. Hypothesis 1b. We will use linear regression to test the relationships 
between parent behaviors and child outcome at 20 weeks (i.e., spoken language 
composite). The regression will include main effect terms for both treatment and 
parent behavior as well as the interaction term, while controlling for baseline 
values of the parent and child measures. Various parent confounders will be 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 9 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
evaluated as well (e.g., SCL-90-R severity score). The main effect of the parent 
behavior will test the contribution of PILI, whereas the interaction term will test 
the value of the combined treatment. These analyses will be done separately with 
two parent behavior measures (parent verbal responsiveness composite and 
quality of caregiver involvement score). 
Analyses will be repeated for secondary outcome measures. 
Aim 2. In the addressing hypotheses 2a, b, and c, we will identify biomarkers 
associated with FXS using a regression model for marker expression with 
grouping of phenotype (i.e., disease state or respond to treatment) as a predictor 
with important clinical cofounders as covariates. The marker performance will be 
evaluated using receiver operating characteristic (ROC) curves to test which 
biomarkers are statistically better diagnostic and prognostic tests for FXS. We will 
further develop predictive signatures of elements involved in MEK/ERK and Rho 
GTPase signaling pathways in response to lovastatin using PAM, or other pattern 
recognized methods. The potential biomarkers are phosphorylation of S6K1, AKt, 
EIF4E, and ERK/MEK as well as levels of IL-1, IL-6, IL- 10, MCP-1, IL-1alpha, 
IL-1beta, MMP-9, and MIF. 
Based on the findings of McDuffie et al. (2016, American Journal on Intellectual and 
Developmental Disabilities) statistical power for this study is expected to be 
sufficient with a subject enrollment of 50. In the McDuffie study, a treatment effect 
was demonstrated with the same outcome measure and same age range in a sample 
size of 10 per group. In this multimodal study, it is expected that the effect of the 
drug, if it is to be clinically meaningful, will be at last as large as the effect of the 
language intervention by itself in the 2016 study. In fact, the expectation is to see 
expect synergistic effects with the language intervention amplifying the effect of the 
drug. 
11) Procedures Involved 
Utilizing consent form C we will first recruit up to 30 participants with 
neurodevelopmental disorders (including Down syndrome, Autism Spectrum 
Disorder, and fragile X syndrome) who are between 6- and 23-years of age and who 
are here at the MIND Institute participating in other projects. These participants will 
serve as pilot subjects to enable the project clinicians who will eventually implement 
the PILI to practice and optimize the interaction strategies that will ultimately be 
taught to the mothers’/caregivers of subjects enrolled under consent forms A and B. 
The pilot participants will be seen for a single visit here at the MIND Institute. 
Project clinicians will interact with each of these pilot participants for approximately 
20 minutes using one of the wordless picture books that will potentially be used in 
the following phase of the study. Although the ultimate goal of the project will be to 
teach the parent to interact directly with the child while the clinician provides 
coaching to guide the parent-child interaction, these sessions will involve an 
interaction between the clinician and the child. The goal of these direct interactions 
between the project clinician and the 30 pilot participants is to practice the strategies 
and procedures for the narrative intervention that will be taught to parents in the next 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 10 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
phase of the project. That is, the project clinicians will use these interactions to: (a) 
determine which wordless picture books are acceptable for use in the project, (b) to 
refine the story scripts that parents will use to introduce the book content, and (c) to 
determine how many teaching episodes can be incorporated into the shared book 
reading activity.  
We propose to conduct a study of the efficacy of the adapted PILI program during the 
first 18 months of the IDDRC funding period.  We expect to enroll up to 30 
participants and employ a series of single-case designs and PILI vs. treatment-as-
usual group comparison design, with the latter group receiving no intervention other 
than what they are already receiving in the community and will participate only in 
pre- and post-treatment assessments. The treatment-as-usual participants will have 
the opportunity to go into the multimodal study, or clinical trial portion of the project, 
which will serve to maintain the participant’s commitment and participation in the 
absence of treatment. Note that there are many reasons to believe that the adapted 
PILI program will be efficacious. These include evidence from other language- 
disordered populations of the utility of narrative as a good context for intervention for 
this age group and also evidence of the importance of parental verbal responsiveness 
(as embodied in PILI) to language development throughout childhood and into 
adolescence for individuals with FXS from longitudinal observational studies. 
Following the PILI only component, we will open enrollment into the clinical trial 
utilizing consent form B, and begin randomizing participants to lovastatin or placebo 
while receiving PILI.  
In addition to the above studies,  a separate study ( ICF D) examining the feasibility 
of implementing PILI in a younger population of boys with FXS (ages 5- to 8-years 
of age) and their biological mothers will be conducted. We expect to recruit 
approximately 3 children whose participation will last approximately 3-6 months. 
The study implemented for this younger age group will follow similar procedures as 
described for the older children in consent form A, with the exception that the study 
materials will be adapted for children who are verbal but who are at the beginning 
stages of language development. Participation in this study will not require any visits 
to the MIND Institute; all information will be gathered through questionnaires and 
interactions via SKYPE. 
To summarize, there will be four consent forms: one for the pilot participants who 
will interact with the project clinicians for the purposes of staff training  (consent 
form C), one in Phases 1 and 2 for the purposes of collecting data on the preliminary 
efficacy of PILI (consent form A), one for the clinical trial during Phase 3 (consent 
form B) and one for the 5- 8-year old cohort (consent form D).Patients who do not 
receive the PILI intervention in Phase 2 will be offered the opportunity to participate 
in Phase 3. All participants being consented under form D will be consented over the 
phone. Additionally, because of the young age and developmental level of these 
participants (consent form D), we will not be conducting assent procedures. 
 
 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 11 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
11 (a). Efficacy/Behavioral Assessments 
Parent-Implemented Language Intervention (Consent Form Versions A, B, and D): 
The parent-implemented language intervention will be delivered entirely in the 
participants’ homes through VTC over 20 weeks. Each session will be delivered by 
an ASHA-certified Speech Language Pathologist (SLP) in collaboration with a 
Board- Certified Behavior Analyst (BCBA).  
At the end of the baseline assessment procedures (described subsequently), the SLP 
and BCBA will provide an overview of the intervention program. The 
parent/caregiver will be given a MacBook Pro laptop computer and tablet with 
preinstalled VTC software (e.g., Skype). Project staff will demonstrate use of VTC 
software and arrange a time for a practice session once the family returns home. The 
first VTC intervention session will be scheduled within 5 weeks of baseline. VTC 
support will be provided by the Administrative Core. 
Participants will receive parent education sessions covering strategies to support 
language development and to reduce challenging behaviors. Each parent education 
session will focus on (a) introducing or reviewing the rationale, procedures, and 
examples of parent use of PVR and behavioral strategies and (b) providing the 
parent/caregiver with reflective feedback and opportunities for joint problem solving 
during review of videos from previous sessions. Parent education sessions also will 
include power-point presentations and written handouts. All written, graphic, and 
video- recorded materials for parent education sessions as well as the recorded parent 
and parent/child sessions will be accessible to the parent/caregiver and clinician using 
a cloud-based system (e.g., Dropbox). Parent education sessions will not involve the 
child. 
Following delivery of the parent education sessions, families will participate in one 
45-min parent/child coaching session per week. The procedures for the parent 
education and coaching sessions are adapted from McDuffie et al. (2013). All 
sessions will be scheduled at the family’s convenience and delivered in the home by 
VTC (e.g., Skype). The parent/child coaching sessions will be embedded within the 
context of an interactive, shared story-telling activity. Wordless picture books 
appropriate for 10- to 17-year- olds with IDD will be used during the intervention. 
During coaching sessions, the SLP will provide real-time guidance to the 
parent/caregiver to increase use of verbally responsive language input including: (a) 
models of diverse vocabulary; (b) models of targeted grammatical constructions; (c) 
intonation prompts and open- ended questions to prompt child communication; and (d) 
recasts of child utterances to provide contingent feedback in the form of more 
advanced language that expresses the child’s intended meaning. The BCBA will be 
available during the coaching sessions to assist with the management of challenging 
behaviors. 
Parents/caregivers will also complete an independent homework session each week 
with their child to provide additional practice in effectively implementing the shared-
story book reading activity. Parents/caregivers will record and upload this session to 
the clinical team using a cloud based system (e.g., Dropbox). The clinical team will 
watch the session and provide written and oral feedback to the parent/caregiver based 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 12 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
on their observations of the parent/child interaction. Finally, the parent/caregiver and 
child will participate in one additional book sharing activity during each week which 
will serve as the context for data collection. Intervention targets will be 
individualized. Language goals for the child will be selected based on the results of 
the baseline spoken language sampling procedures. PVR targets for the 
parent/caregiver will be selected based on results of the baseline shared storytelling 
and structured interaction procedures. Child challenging behavior goals will be 
selected based on the results of the baseline Functional Behavior Assessment. The 
SLP and BCBA will coordinate their planning to ensure that targets and procedures 
form a consistent and coherent plan. As is customary in PILI, the parent/caregiver 
will be involved in prioritizing targets. 
Child Assessment Measures 
The following measures will be used to verify that participants meet screening 
criteria, verify that random assignment has yielded equivalent groups, and provide 
variables that can be examined as potential moderators of treatment response. To 
ensure accurate scoring and for study training purposes some assessments may be 
audio and/or video recorded at the pre and post visits. Any assessments or study 
procedures deemed not appropriate for a subject based on their cognitive abilities and 
behaviors will not be completed with the exception of those required for inclusion/ 
exclusion criteria and safety assessments.  
i. 
Clinical Evaluation of Language Fundamentals – 4 (CELF-4): ICF A and B 
A standardized norm- referenced assessment that provides subtests assessing 
sentence comprehension, following directions, formulated sentences, and 
written language (15 min). 
ii. 
Leiter International Performance Scales: ICF A and B 
A published, standardized, norm-referenced test designed to measure 
developmental functioning and IQ for individuals ranging in age from 2 years 
to adulthood. Minimal verbal directions are used in the administration to 
allow assessment of cognitive ability independent of language ability. The 
tasks require matching shapes, completing visual sequences through card 
placements, and detecting sequences and component parts. The figure 
ground, form completion, sequential order, and repeated patterns subtests 
will be administered to determine Brief IQ (45 min).  
iii. 
Comprehensive Assessment of Spoken Language (CASL): ICF A and B 
A norm referenced, orally administered standardized test used to measure 
language comprehension, language expression, and language retrieval in the 
following linguistic domains: lexical/semantic, syntax, and pragmatics. The 
test has age-based norms which can be used to detect language impairment 
(45 min,). 
iv. 
Test for Reception of Grammar – 2 (TROG-2): ICF A and B 
A norm referenced, standardized test of grammar comprehension. For each 
item, the participant points to the one drawing from a choice of four that 
matches the meaning of a word, phrase, or sentence spoken by the examiner 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 13 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
(10 min). 
v. 
Peabody Picture Vocabulary Test – 4 (PPVT-4): ICF A and B 
A norm referenced, standardized test of vocabulary understanding. For each 
item, the participant points to the one picture out of four that corresponds to a 
single word spoken by the examiner (10 min). 
vi. 
Expressive Vocabulary Test – 2 (EVT-2): ICF A and B 
A norm referenced, standardized test of spoken vocabulary. For each item, 
the participant names the pictured object (10 min). 
vii. 
The Autism Diagnostic Observation Schedule-Second Edition (ADOS-2; 
Lord et al., 2012): ICF A and B  
The assessment will provide a continuous metric of autism symptom severity 
for use in characterizing the participant sample and as a potential moderator 
of treatment response. The ADOS is a gold-standard measure of current 
symptoms of autism. Total scores will be used to assign a severity score. 
Scores range from 1 to 10, with higher scores reflecting more severe 
impairment (45 min)  
viii. 
Functional Assessment of Challenging Behavior (FACB): ICF A and B 
A functional behavior assessment (FBA) of child challenging behavior will be 
used to inform the behavior plan developed by the BCBA. The FBA will 
have three components: (1) The Functional Assessment Interview Form (FAI; 
O’Neill et al., 1997), which is a structured interview with the parent/caregiver 
to learn about the antecedents, consequences and topographies of child 
challenging behavior; (2) Questions About Behavioral Function (QABF; 
Matson & Vollmer, 1995): A caregiver-report survey to assess the potential 
functional value of the challenging behaviors for the individuals; and (3) Brief 
Experimental Functional Analysis (Wacker et al., 2004). An examiner-
implemented procedure in which potential antecedents and consequences are 
experimentally manipulated to identify the environmental variables 
controlling the challenging behaviors (45 min). 
ix. 
Child Spoken Language: ICF A and B 
The conversation and narration procedures described in Preliminary Studies 
will be administered at the baseline and post-treatment visits. Alternate 
versions of conversation and narration materials will be administered at the 
two visits and counterbalanced.  
Neurobehavioral Analysis Core staff blind to hypotheses and participant 
characteristics will transcribe/code. A spoken language ability composite will 
be obtained for each assessment time by taking a weighted mean of variables 
reflecting talkativeness, fluency, intelligibility, vocabulary diversity, and 
syntactic complexity in combined narrative and conversational samples. This 
composite will provide a broad-based and robust measure of spoken language 
ability and serve as the primary outcome measure. Exploratory analyses will 
evaluate the separate contributions of the variables included in the composite 
(30 min). 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 14 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
x. 
The Social Communication Questionnaire (SCQ): ICF D 
A widely used informant report checklist that evaluates communication and 
social skill deficits common to those with symptoms of autism. This brief 
questionnaire will be completed by the participant’s parent/caregiver (10 
min). 
xi. 
The Vineland Adaptive Behavior Scales (VABS): ICF D 
The VABS is a widely used informant report checklist that will be used to 
assess four domains: communication; self-care; social skills; and maladaptive 
behavior. It will be completed by the participant’s parent/caregiver (30 min). 
xii. 
Childhood Autism Rating Scale, Second Edition (CARS-2): ICF D 
An examiner completed behavioral rating scale used to evaluate symptoms of 
autism following a direct observation of a child. The parent-child structured 
interaction will be used as the context which is evaluated for this measure.  
xiii. 
The Aberrant Behavior Checklist (ABC): ICF A, B, and D  
A behavior rating scale completed by the parent/caregiver that is frequently 
used to examine treatment effects on challenging behaviors for individuals 
with FXS. The scale is comprised of 58-items in the following domains: (1) 
irritability, agitation, crying; (2) lethargy, social withdrawal; (3) stereotypic 
behavior (4) hyperactivity, noncompliance; and (5) inappropriate speech (15 
min). The Sansone et al. (2011) FXS-normed ABC scoring measures will be 
used. The social avoidance subscale score will be a secondary clinical 
endpoint. 
xiv. 
The Repetitive Behavior Scale-Revised (RBS-R; Lam & Aman, 2007): ICF 
A and B  
A conceptually derived and empirically validated informant report scale that 
assesses the presence of a wide variety of repetitive behaviors frequently 
associated with autism in the domains of: Ritualistic Sameness, Self Injury, 
Stereotypic Behaviors, Restricted Interests, and Compulsive Behaviors (10 
min). 
xv. 
The Anxiety Depression and Mood Screen (ADAMS): ICF A and B 
An informant report questionnaire that serves as a screening instrument to 
determine anxiety, mood, and depression among individuals with intellectual 
disability. The respondent is asked to rate the extent to which their child 
displays target symptoms. (10 min). 
Parental Assessment Measures: 
i. 
Kaufman Brief Intelligence Test (K-BIT; Kaufman & Kaufman, 2004): ICF 
A and B  
Assessment will be administered to determine IQ (25 min).  
ii. 
Symptom Checklist-90-R (SCL-90-R: Derogatis, 1993): ICF A, B, and D 
This assessment is used to determine the presence of mental health symptoms 
via the global severity index standard score (10 min). 
iii. 
The Five-Minute Speech Sample (FMSS): ICF D  

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 15 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
A procedure designed to measure expressed emotion in the parent’s attitude 
toward their child. The sample is elicited by instructing the parent/caregiver 
simply to talk about the child for five minutes without interruption from the 
examiner. The FMSS is audio recorded, transcribed, and coded for 
dimensions of emotional climate, such as maternal criticism, emotional over-
involvement, and warmth. These dimensions have been found to relate to 
maternal behavior and to predict symptom change in individuals with autism, 
schizophrenia, and many other conditions (5 min).  
iv. 
Parenting Stress Index (PSI): ICF A, B, and D 
A 36-item measure of the degree of stress in the parent- child relationship (10 
min).  
v. 
Parenting Sense of Competency Scale (PSOC): ICF A, B, and D 
A 16-item measure of parenting satisfaction and perceived self-efficacy (10 
min.). 
vi. 
Family Background Questionnaire: ICF A, B, and D 
Parent report of family background information, for example parent’s 
educational attainment, parents’ occupation, school setting, son’s diagnoses, 
additional family members, child medications, household income. 
Information from this questionnaire will allow us to describe our sample in 
detail.   
vii. 
Post Treatment Survey: ICF B 
A 32 item parent questionnaire regarding participation in the study 
intervention. 
Parent-Child Assessment Measures:  
Parent use of targeted intervention strategies and child spoken language will be 
assessed during joint book reading within two contexts at both the pre- and post-
treatment assessment. The contexts will be 1) at the clinic visit, and 2) in the family 
home via distance teleconferencing. The parent/caregiver and child will look at a 
wordless picture book together and the parent/caregiver will be instructed to look at 
each page of the book and tell the story with his/her child as he/she usually would. 
A set of two wordless picture books will be used in each sampling context and the 
books will be randomly assigned to participants and counterbalanced at the pre- 
and post-assessment time points. The following parent and child variables will be 
obtained from each context and average to create composite variables. Parent 
variables: story-related talking, open-ended questions, use of expansions, use of 
intonation prompts. Child variables include: Mean length of utterances, number of 
different words, story-related talking, intelligibility, mazes, off-topic utterances, 
and repetitive utterances. Each sample will last approximately 15 minutes. 
i. 
Parent/Child Narrative Task 1(Clinic): ICF A and B 
The parent/caregiver will tell a story with the child using the wordless picture 
books  Frog Where are You (version A) or One Frog Too Many (version B). 
The parent/caregiver will be encouraged to look through/familiarize 
themselves with the book in advance of the language sampling session (15 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 16 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
min, Pre/Post Consent Form Versions A and B). 
ii. 
Parent/Child Narrative Task 2 (Home): ICF A, B, and D  
Parent/caregiver will tell a story from a wordless picture book from a 
selection of books that will not be used during the intervention. The 
parent/caregiver will be encouraged to look through/familiarize themselves 
with the book in advance of the language sampling session.). 
iii. 
Parent/child structured interaction – Child: ICF D 
The parent will interact with the child during four activities: joint book 
reading, preparation of a snack, completion of a goal-directed construction 
activity, and free play. The mother will be instructed to participate and 
involve the child as much as possible. Sessions will be coded to determine 
maternal use of responsive verbal interaction strategies, child spontaneous and 
prompted communication acts, and child challenging behaviors (20 min). 
 
The following are exploratory measures: 
i. 
The Clinical Global Impressions Scale–Severity (CGI-S) and Improvement 
(CGI-I) (Busner & Targum, 2007): ICF B  
These standardized assessment instruments are widely used in drug trials to 
enable the clinician to utilize history from the parents or caregiver and  
incorporate it into a clinical rating, first for severity, and then for clinical 
follow-up. The CGI-S will be used at the pre-treatment assessment to judge 
symptom severity and the CGI- I will be used at the 3 month and 6 month 
visits. 
ii. 
The Visual Analogue Scale (VAS): ICF B  
The measure will be used to assess parental impressions of progress in two 
key symptoms: spoken language impairment and social impairment. The 
distance of the mark from one end is used as the outcome variable for 
analysis. The VAS will be administered at each visit. The VAS has been 
effectively used as an outcome measure in other FXS drug trials (Erickson et 
al., 2011; Paribello et al., 2010; Leigh et al 2013). 
11 (b). Medical/Safety Assessments (Consent Form B):  
The schedule of procedures is also listed in a table format below: 
Assessment 
Screening/Baseline 
Visit 1 
(Week 1, Day 0) 
Visit 2 
(Week 10 ± 3 Days) 
Visit 3 
(Week 20 ± 3 Days) 
Informed Consent  
X 
 
 
Inclusion/Exclusion Criteria 
X 
 
 
Medical History 
X 
 
 
Vital Signs 
X 
X 
X 
Physical Exam 
X 
X 
X 
Neurological Exam 
X 
X 
X 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 17 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
Concomitant Medications 
X 
X 
X 
Adverse Events 
X 
X 
X 
Clinical Labs 
X 
X 
X 
Biomarkers  
X 
X 
X 
Leiter-R (45 min.) 
X 
 
 
ADOS-2 (45 min.) 
X 
 
 
CGI-S 
X 
 
 
CGI-I 
 
X 
X 
VAS 
X 
X 
X 
Language Assessments 
 
 
 
CELF-4 (15 min.) 
X 
 
X 
CASL (45 min.) 
X 
 
X 
TROG-2 (10 min.) 
X 
 
X 
PPVT-4 (10 min.) 
X 
 
X 
EVT-2 (10 min.) 
X 
 
X 
FACB (45 min.) 
X 
 
 
Child Spoken Language (30 min.) 
X 
 
X 
Parent Narrative Task 1 (15 min.) 
X 
 
X 
Parent Narrative Task 2 (15 min.) 
X 
 
X 
Parental Assessments 
 
 
 
K-BIT-2 (maternal) (25 min.) 
X 
 
 
Parent Questionnaires 
 
 
 
ABC (15 min.) 
X 
X 
X 
ADAMS (10 min.) 
X 
X 
X 
RBS-R (10 min.) 
X 
X 
X 
PSI (10 min.) 
X 
 
X 
PSOC (10 min.) 
X 
 
X 
Family Background 
Questionnaire (10 min.) 
X 
 
 
SCL-90 (maternal) (10 min.) 
X 
 
X 
Post Treatment Survey 
 
 
X 
Dispense Medication 
X 
X 
 
Randomization to lovastatin or placebo will be conducted by the UCDMC pharmacy 
using a computer algorithm. IDS will over-encapsulate the active study medications and 
prepare the placebo capsules prior to dispensing. Equivalence of the groups on these 
stratification variables, as well as other variables (e.g., child autism symptom 
severity and maternal IQ), will be tested, with any significant differences accounted 
for by inclusion of covariates in the primary analyses. 
The dose will range from 10 to 40 mg of lovastatin or placebo depending on 
tolerance of the dose. The dose will start at 10 mg per day and will be increased by 
10 mg increments on a weekly basis from study weeks 1 through 4 as listed below. 
Dosing will occur once per day in the evening. Dose tolerance will be assessed through 
a weekly phone call or email contact conducted by a study physician during the 
titration period and a dose decrease can be made if necessary. If a dose decrease is 
made between weeks 2 and 4 no further dose titrations will occur and subject will be 
considered on a stable dose throughout the remainder of the titration period and study. 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 18 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
If more than one dose change is needed, the subject will be discontinued from the 
study. Once a stable dose is reached, subjects will remain at the designated dose 
through visit 3 and will be contacted approximately every other week by study staff to 
assess for possible adverse events and verification of proper dosing. Study participants 
will be dispensed study medication at visits one and two and will discontinue dosing 
after completing visit 3. 
Week 1: 10 mg (Day 1-7) 
Week 2: 20 mg (Day 8-14) 
Week 3: 30 mg (Day 15-21) 
Week 4: 40 mg (Day 22- 28) 
Week 5-20: 40 mg or OTD (Day 29- 140)  
Our dosage model takes into consideration the biphasic and pleiotropic effects of 
statins. The biphasic effect can be explained by the higher affinity for the enzymes 
that catalyze non-sterol product formation than for the cholesterol biosynthesis 
enzymes. Low doses of statins mainly affect cholesterol synthesis, while high doses 
affect mevalonate-derivative intermediates, which are essential for the prenylation of 
proteins and Ras activation (Li, et al., 2007). The pleiotropic effects of statins suggest 
that the sustained use of statins (more than 2 weeks) causes PTEN up regulation, 
which inhibits the PIK3/AKT pathway; and that higher acute dose administration of 
statins will inhibit Ras, which is our targeted effect. (Ludman, et al., 2009).  
Adverse events (AE) will be documented along with any changes in study medication 
dose or use of other medications. Each AE will be scored for severity, frequency, and 
relatedness to lovastatin. All serious adverse events will be reported to our IRB as 
required by reporting guidelines. The DSMB will also review the study data and 
assess for safety on a regular basis. 
Safety labs, listed below, will be conducted at all three visits through the UC Davis 
health system pathology laboratory. These laboratory tests will assess for creatine 
phosphokinase (CPK) as rare irritation to the muscle have been reported with statin 
treatment. The liver function studies will be utilized to rule out irritation to the liver 
and the urinalysis will screen for rhabdomyolysis. The lipid panel will assess that 
cholesterol and triglycerides remain within the normal range. Due to the processing 
requirements for the lipid panel, blood draws will be done while subjects are fasting. 
If there is any sign of myopathy, muscle pain or allergic reaction the medication will 
be discontinued. Pregnancy testing will only be conducted on female participants of 
child-bearing potential. 
Safety Lab Tests 
Chemistry 
Hematology 
Urinalysis 
Creatine Kinase 
Hemoglobin 
pH 
Potassium 
Hematocrit 
Color 
Chloride 
WBC 
Clarity 
Carbon Dioxide 
RBC 
Specific Gravity 
BUN 
MCV 
Occult blood 
Creatinine 
MCH 
Urobilinogen 
Glucose 
MCHC 
Ketones 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 19 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
Calcium 
RDW 
Protein 
Protein 
MPV 
Glucose 
Albumin 
Platelet Count 
Pregnancy spot 
urine 
ALP 
Neutrophils 
 
AST 
Lymphocytes 
 
ALT 
Monocytes 
 
Bilirubin 
Eosinophil 
 
Cholesterol 
Basophils 
 
HDL cholesterol 
 
 
Triglycerides 
 
 
Serum Pregnancy 
(βHCG) 
 
 
 
In addition to the 7ml of blood for safety labs, we will collect approximately 30 ml of 
blood at each visit for biomarker analysis of immune function, MEK/ERK, 
RhoGTPase, and Ca2+ signaling, and cell activation.  
Cytokine and chemokine levels will be measured in plasma using a Luminex based 
multiplex technology to analyze IL-1, IL-6, IL-10, MCP-1, IL-1alpha, IL-1beta, 
MMP-9 levels, and MIF. These will be measured using plasma according to the 
manufacturer’s instructions. A control plasma sample will be run on each plate for 
normalization between plates. The plates will be read on a Bio-Plex 100 (BioRad) 
and analyzed using Bio-Plex Manager software using a 6-point standard curve. 
Levels of cytokines and chemokines that fall below the limit of detection (LOD) are 
assigned a value of LOD/2 to allow for logn   transformation of raw data. Plasma 
levels of TGF- beta will be determined by ELISA as previously described (Ashwood 
et al., 2008).  
To determine the effects of lovastatin treatment on TLR4 activation, we will use 
isolated PBMCs and stimulate the TLR4 receptor with LPS for 48 hr. The 
supernatants will be collected and analyzed for IL-1, TNF-alpha, IL-6, MMP-9, and 
MIF using luminex multiplex analysis. Quantification of Molecular Biomarkers: 
MMP-9 activity will be measured in plasma of participants, which will be obtained 
from whole blood samples by centrifugation and aliquots will be stored at -80°C until 
use. Samples will be coded and the code revealed after results have been obtained. 
MMP activity will be quantified by zymogram analysis. Levels of total and 
phosphorylated ERK ½ will also be assessed by Luminex. In addition, kinetic 
analysis of the early phases of ERK activation will be employed to determine the 
feasibility of using pERK in PMBCs as an indicator for responsiveness to lovastatin 
treatment. PMBCs will be isolated from CPT tubes, counted, and stimulated by PMA 
to activate protein kinase C-mediated phosphorylation of ERK. Cells will be fixed at 
different time points by the addition of methanol, permeabilized and immunostained 
for phospho- ERK and analyzed in a flow cytometer as described in Weng, et al. 
(2008). 
The mechanistic effects of lovastatin on MEK/ERK signaling and Rho GTPase 
activation will also be studied. The goal of these studies is to determine: (1) the 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 20 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
effects of lovastatin on Ras GTPase and Rho GTPase (RhoA, Cdc42 and Rac1) 
activation in antigen presenting cells (APCs); (2) the effects of lovastatin on Ca2+ 
signaling in APCs; and (3) the relative contribution of cholesterol versus isoprenoid 
synthesis inhibition to lovastatin effects on these signaling events in APCs. The data 
obtained in these mechanistic studies will provide insight on therapeutic targets 
which may be useful in developing more targeted treatments and provide the 
groundwork for expanding this work into relevant animal models to examine 
mechanisms by which lovastatin improves neurodevelopmental outcomes. APCs will 
be isolated from PBMCs collected from children with FXS (where baseline values 
will be compared to treatment samples) by panning for cells that adhere to a 
polystyrene tissue culture dish. High content imaging, which enables cell based 
detection of up to five distinct fluorescent markers simultaneously in a multi-well 
format plates (up to 96 wells per plate) will be used to determine: 1) specific APCs as  
identified by cell surface markers (as described in Enstrom et al., 2010); and 2) 
activation of Ras and Rho GTPases as identified by immunocytochemical localization 
of these signaling molecules within the cell, with activated versus inactivated forms 
indicated by plasma membrane versus cytoplasmic localization, respectively (Bar-
Sagi and Hall 2000). 
Real-time Ca2+ oscillations measured with FLIPR will also be studied. This rapid 
throughput technique will be used to measure the onset and properties of 
synchronized Ca2+ oscillations in human monocyte cell cultures at baseline, mid-
treatment, at the end of the trial. This method permits simultaneous measurements of 
intracellular Ca2+ transients in a 96-well format using the FLIPR® Tetra imager 
rapidly (10Hz) and in real-time as we described recently (Cao et al 2012). Cells are 
loaded with Fluo-4 and recordings from each of 96-wells are simultaneously 
acquired for 10 min. We will analyze Ca2+ responses evoked by ATP challenges (1-
200μM) in monocytes to correlate whether differential responses are correlated with 
treatment response as well as cytokine/chemokine profiles.  
To determine the relative contribution of cholesterol versus isoprenoid-dependent 
mechanisms to lovastatin effects on these signaling molecules, we will determine 
whether selective inhibitors of cholesterol synthesis (zaragozic acid) or isoprenoid 
synthesis (perillic aid, manumycin A, GGTI-298, FTI-277) phenocopy lovastatin 
and whether supplementation with mevalonate, cholesterol or isoprenoids (farnesol, 
geranylgeraniol, farnesyl phyrophosphate or geranylgeranyl pyrophosphate) reverse 
lovastatin effects at a cellular level as described in Kim et al., 2009. These assays 
will first be optimized using PBMCs isolated from consenting members of the 
laboratory before being applied to PBMCs isolated from children enrolled in the 
clinical trial. 
12) Data and Specimen Banking 
Retention of Records: 
Records and documents pertaining to the conduct of this study and the distribution of 
IMP, including eCRFs, Informed Consent Forms, laboratory test results, and 
medication inventory records, must be retained by the Principal Investigator for at 
least 2 years after completion or termination of the study, or for the length of time 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 21 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
required by relevant national or local health authorities, whichever is longer. After 
that period of time, the documents may be destroyed, subject to local regulations.  
Records transferred to another party will be de-identified. 
Specimen Banking: 
Samples will be stored until the conclusion of the study after which only samples of 
subject’s consenting to further storage of study samples after the study will be stored. 
13) Data Management and Confidentiality 
Confidentiality: 
Research charts will be kept on the subjects and subject information will be coded to  
protect confidentiality. All charts will be kept in a locked cabinet of a locked file 
room. The identifiers used to identify subjects will be kept in locked offices and/or 
locked cabinets, and the electronic database containing personal information will be 
kept on a secure computer network accessible only to PI’s research team. If 
information from the study is published or presented at scientific meetings, subject 
names and other information that could identify subjects, will not be used. 
The subjects’ health information, along with the identifiers, will be kept with the 
investigator as mentioned, until the conclusion of the study, or when immediate 
access is no longer required. Thereafter, the information may be transferred to a 
records and information management company for long-term storage, or to a 
UCDMC long term storage facility. When the investigator or any regulatory agencies 
no longer require the information (but no sooner) than 5 years, the documents will be 
securely shredded. 
All study personnel will have access to study records, data, and specimens. If 
required, access to study records and data will be made available to representatives of 
the IRB. Enrolled subjects will be made aware that study personnel, and 
representatives of the IRB will have access to their records. This will be included in 
the consent form and will also be thoroughly reviewed during the consent process. 
In addition, every attempt will be made to ensure that the personal and medical 
information of the subject will be kept private; however, we cannot guarantee total 
privacy. The subject’s personal and medical information may be given out if required 
by law. For example, reporting sensitive information (such as child abuse) to state or 
local authorities if necessary. 
The results and data are de-identified to protect patient confidentiality. 
14) Provisions to Monitor the Data to Ensure the Safety of Subjects 
During the clinical trial portion of the study the subject will have a medical 
assessment initially by a study physician to ensure that it is safe for the subject to be 
enrolled in the study. Weekly telephone calls will take place in the first month to 
document any side effects and make dose adjustments if necessary 
Subsequent calls to monitor subject safety will take place approximately every other 
week. Visits will include a medical examination with vitals and growth parameters 
and a review of behavior and side effects. Safety labs will be conducted at all three 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 22 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
visits to ensure the subject is safe to enroll and continue in the study. 
We will carefully monitor study participants for any significant worsening of mood, 
agitation, and impulsivity in our phone calls and in the follow-up medical 
assessments. 
An independent data safety and monitoring board (DSMB) will be established and 
consist of 2 physicians who are not affiliated with the study but have significant 
expertise in conducting psychopharmacological interventions in children with FXS 
and/or autism. In addition, an independent statistician will be a member of the 
DSMB. The first DSMB will examine un-blinded adverse events and clinical data  
after six months from first subject enrolled into the clinical trial component to determine 
if the trial is safe to continue. DSMB meetings will be held annually thereafter until all 
subjects have completed the study. The investigators and staff will remain blinded 
throughout the trial unless there is an adverse event requiring unblinding, when 
medical treatment for a subject would be different based on whether or not they were 
receiving active study drug. 
Any serious adverse events which occur to any subject after being randomized into 
this study and up until 30 days after the last dose of the study drug will be followed 
up for outcome and reported to the IRB according to their reporting guidelines. Mild 
and moderate adverse events considered related to the study medication, but not 
listed in the consent form will be reported to the IRB according to the reporting 
guidelines. Serious adverse events will be reviewed by the principal investigator for 
indications of a change in the overall risk assessment, or need for modification of the 
consent form. 
Written standard operating procedures (SOPs) will be followed to ensure that the 
clinical trial component is conducted and data are generated, documented (recorded), 
and reported in compliance with the protocol, GCP, and the applicable regulatory 
requirements. Quality control (QC) will be applied to each stage of data handling. 
Monitoring, as defined in ICH GCP, Section 1.8, “The act of overseeing the progress 
of a clinical trial, and of ensuring that it is conducted, recorded, and reported in 
accordance with the protocol, SOPs, GCP, and the applicable regulatory 
requirement(s)” will be conducted throughout the conduct of the study. 
The clinical investigator and the institution will permit trial-related monitoring, 
audits, IRB review, and regulatory inspection (FDA or other regulatory body) by 
providing direct access to source data/study documents. 
15) Withdrawal of Subjects 
The investigator has the right to discontinue or withdraw a subject from the study at 
any time. In addition, subjects have the right to voluntarily discontinue study drug or 
withdraw from the study at any time for any reason. Reasons for discontinuation of 
study drug or withdrawal from the study may include, but are not limited to, the 
following: 
• Subject withdrawal of consent at any time 
• Any medical condition that the investigator determines may jeopardize the 
subject’s safety if he continues in the study 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 23 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
• Investigator determines it is in the best interest of the subject 
• Subject non-compliance 
Discontinuation from Study Drug:  
Subject must discontinue study drug if they experience any of the following: 
• Hematological events 
• Subject unable to continue to comply with study requirements 
Subjects who discontinue study drug prematurely will be asked to return to the clinic 
for a study completion/early termination visit and may undergo follow up 
assessments. The primary reason for premature study drug discontinuation should be 
documented on the appropriate eCRF.  
Withdrawal from Study: 
Every effort should be made to obtain information on subjects who withdraw from the 
study. The primary reason for withdrawal from the study should be documented on 
the appropriate eCRF. Subjects will not be followed for any reason after consent has 
been withdrawn. 
16) Risks to Subjects 
Venipuncture: 
The risks of blood collection from a vein include discomfort at the site of the needle 
stick, possible bruising and swelling around the site of the needle stick, rarely an 
infection or blot clot, and uncommonly feeling faint or dizzy from the procedure. 
Due to the type of safety labs being conducted for this study, fasting blood draws are 
required, which may cause discomfort to the subject. 
Privacy: 
There may also be risks to subjects’ privacy. Study staff at the MIND Institute will 
store study records and other information in a secure location and will grant access 
only to those who require it. However, even these safeguards cannot guarantee 
absolute protection of the data. 
Unidentified or unforeseen risks: 
The results of the subject’s lab tests may be outside the normal range (too high or too 
low). If this occurs, the study doctor will talk to him or her and may ask to have him 
or her repeat one or more tests during the study. Since the study medicine is 
experimental when taken alone or in combination with other medications, it may 
cause other adverse effects that are currently still unknown. If any new information 
comes out that might affect the subject’s decision to continue with the study, he or 
she will be informed. 
Sometimes people have an allergic reaction to medicines. Allergic reactions may be 
mild (rash, hives) to severe (an acute or sudden drop in blood pressure to shock 
levels with loss of consciousness and/or associated with seizures, including the 
possibility of death). 
Lovastatin Risks: 
Lovastatin has generally been well tolerated and adverse reactions have usually been 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 24 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
mild and transient. Patients will be advised to report promptly any symptoms that 
may indicate liver injury, including fatigue, anorexia, right abdominal discomfort, 
dark urine, or jaundice. The package insert lists all risks associated with the 
medication and adverse reactions possibly, probably, or definitely related to study 
medication are listed below: 
 
More Common 
Less Common 
• Feeling weak 
• Abdominal pain 
• Constipation 
• Diarrhea 
• Upset stomach 
• Flatulence 
• Nausea 
• Muscle Cramps 
• Muscle pain 
• Dizziness 
• Headache 
• Rash 
• Blurred vision 
• Irritability 
• Chest pain 
• Acid reflux 
• Dry mouth 
• Vomiting 
• Leg pain 
• Shoulder pain 
• Joint pain 
• Insomnia 
• Burning, prickling, or tingling 
• Hair loss 
• Itching 
• Eye irritation 
Lovastatin may elevate creatine phosphokinase and transaminase levels, which may 
be considered in the differential diagnosis of chest pain. Lovastatin is also less 
effective in patients with the rare homozygous familial hypercholesterolemia and may 
raise serum transaminases. Due to possible risks associated with lovastatin, liver 
enzymes will be checked at all three study visits. 
17) Potential Benefits to Subjects 
Patients may receive no direct benefit from participation in this study. However, 
participation will help investigators better understand autism and contribute to the 
scientific knowledge of FXS as well as potentially lead to improved testing and 
treatment options. 
Half of the participants will receive the Parent-Implemented Language Intervention 
(PILI) under consent form A, the remaining half of participants will have the option 
to participate in the clinical trial portion of the study under consent form B, at which 
point they will be guaranteed to receive the PILI intervention.  
All participants will receive the Parent-Implemented Language Intervention (PILI) 
under the clinical trial portion of the study, consent form B. In addition to PILI, half of 
the patients will be randomized to take lovastatin and may experience a beneficial 
response to lovastatin including heightened response to PILI with language 
improvements and reduction of problematic behaviors of FXS including ADHD, 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 25 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
aggression, and anxiety. All participants under consent form B will also benefit by 
receiving physical exams, cognitive assessments, and blood tests. 
18) Vulnerable Populations 
The patient population to be studied is developmentally disabled children with fragile 
x syndrome. We have done research with developmentally disabled and cognitively  
impaired individuals of all ages for many years. The consent process for individuals 
without the cognitive ability to consent will be completed by the parent, caregiver, or 
legally authorized representative (LAR), and no procedures will be done with any 
subjects without consent of either subject or parent/caregiver/LAR. 
19) Sharing of Results with Subjects 
At the conclusion of the study, the possible medical benefit from the study will be 
reviewed with the subject and his or her parent/guardian. Any laboratory work 
considered standard of care will be available for patients at their request. Psychological 
assessment scores may be communicated to the subjects if it does not impact future 
testing. If a subject has to be unblinded for emergency purposes then the subject will be 
notified by the principal investigator or study physician. Unblinding will be conducted in 
accordance with the MIND Institute’s SOP# 500-014: Study Subject Unblinding Process. 
The results of the study may also be published or presented at scientific meetings 
including peer reviewed scientific journals that will be made publicly available 
through PubMed Central. In addition, after publication the results will be posted on 
the MIND Institute website under clinical trials 
20) Setting 
The MIND Institute Research Clinic has a large waiting room with divided areas for 
each family, 10 examination rooms, a consult room, a chart/supplies room, a vitals 
room, and 2 coordinator stations totaling approximately 15,000 square feet. There 
are one-way mirrors and a state of the art digital video recording systems in each of 
the 4 observation rooms. It is in the clinical research space that subjects will be seen. 
We have a research phlebotomy lab adjacent to the patient evaluation rooms, where 
all blood samples will be drawn for this study. The private family rooms may be 
utilized for recruitment purposes and the MIND Institute also has many non-patient 
areas where subject phone contacts and study records can be stored. 
The PILI assessments will be completed through secure video teleconferencing so 
families may complete the PILI in the comfort of their homes. 
21) Resources Available 
Drs. Hagerman, Leigh,  and Angkustsiri will follow patients through their treatment 
with the study drug, until they have completed the study. Designated qualified staff 
will conduct cognitive and behavioral assessments as required for the study. 
Coordinators and research assistants will be responsible for contacting and screening 
potential patients, scheduling and coordinating all patient appointments and visits, 
coordinating the processing of all samples, meeting with study monitors, as well as 
organizing all relevant supplies and data for the study. Transcriptionists will be 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 26 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
responsible for transcribing and coding all language samples for purposes of 
deriving the primary outcome measures. The number of physicians, coordinators, 
and raters is sufficient to successfully carry out the protocol to completion in the 
specified timeline. Study protocol specific training will occur and be documented 
prior to staff conducting assessments or procedures and all study staff will be  
approved and designated by the principal investigator. 
The UC Davis Medical Center Investigational Drug Services pharmacy will store, 
over-encapsulate the active study medications, prepare the placebo capsules, and 
dispense the study drug. 
22) Prior Approvals 
All research staff will be required to complete CITI training per UCD research 
requirements and will be adequately trained to perform their allotted tasks as 
approved by the principal investigator. 
23) Provisions to Protect the Privacy Interests of Subjects 
Sections 12, 13, and 14 address various ways the privacy interests of subjects are 
protected. 
In addition, subject medical information obtained by this study is confidential. Data 
generated by this study must be available for inspection by representatives of the 
USA FDA, national and local health authorities, and the IRB.  
With the subject’s permission, medical information may be given to his or her 
personal physician or other appropriate medical personnel responsible for his or her 
welfare.  
Study Records will be maintained on site in non-patient areas accessible only to 
study staff. The informed consent process and study assessments conducted by study 
physicians or raters will be carried out in private areas to ensure patient privacy and 
only approved study staff will have access to subject information. 
24) Compensation for Research-Related Injury 
If the subject is injured as a result of being in this study, the University of California 
will provide necessary medical treatment. Depending on the circumstances, the costs 
of the treatment may be covered by University or may be billed to the subject’s 
insurance company just like other medical costs. The University does not normally 
provide any other form of compensation for injury. 
25) Economic Burden to Subjects 
There is no charge for the subject to participate in this study. Neither the subject nor 
his or her insurance carrier will be charged for taking part in the research. All costs 
associated with the study will be paid by the sponsor/department. 
Possible expenses to the subject’s family include time spent at the clinic as well as 
expenses for travelling. Subjects will not be paid just for taking part in this study (i.e., 
compensated). However, all eligible research subjects, who would not otherwise be 
able to participate due to the cost of travelling to the MIND Institute (e.g., flights, 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 27 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
gas, lodging), will be reimbursed for actual costs incurred.  
Since fragile X syndrome is a rare disorder, we often need to recruit nationwide to  
meet recruitment goals and more importantly to provide an opportunity for the non-
local families to participate in research that is not available near their residence. Each 
family's travel expenses will vary greatly due to their geographic location.  
Costs of travel may include, but are not limited to economy airfare, car mileage, 
lodging, bridge tolls, parking garage fees, taxis, rental cars or gas reimbursement for 
rental cars. Reimbursement will be based off of paid receipts submitted by families 
per UCDMC reimbursement policy. Travel reimbursement is based off of employee 
reimbursement guidelines enforced by the Department of Psychiatry and Behavioral 
Sciences and University policy. Reimbursement checks will typically be mailed 4-10 
weeks from submission of paid receipts following the completed study visit. 
26) Consent Process 
Patients will be recruited and consented at the UC Davis MIND Institute. The consent 
will conform to HRP-90 and HRP-091. 
The permission will be obtained from both parents unless one parent is deceased, 
unknown, incompetent, or not reasonably available, or when only one parent has legal 
responsibility for the care and custody of the child. If the child has the cognitive 
capacity to assent, then they will be assented to participate. Study staff will assess the 
capacity to consent using the Capacity Assessment Checklist for Informed Consent 
with Cognitively Impaired Subjects. Parents or LARs whose child turns 18 
throughout the course of the study will be consented with the surrogate decision 
maker form. 
All parents or LARs will sign a HIPAA authorization for research. 
27) Process to Document Consent in Writing 
We will be following “SOP: Informed Consent Process for Research, HRP-090” and 
“SOP: Written Documentation of Consent, HRP-091.”    
28) Drugs or Devices 
The investigational product will be dispensed by bottle number by the Investigational 
Drug Services Pharmacy (IDS). All investigational product supplies must be kept in a 
secure locked cabinet or location, with access limited to authorized clinical 
investigation personnel. The contents of each bottle will be blinded using labels that 
contain a unique bottle number. The randomization schedule will match a subject 
number to the unique bottle number and an appropriate dose. Upon completion of 
screening evaluations for each subject, the Investigator or appropriate designee will 
contact IDS to randomize subject and dispense investigational product. The 
Pharmacist at IDS will select the correct bottle of investigational product and 
distribute the bottle to the Investigator or designee. Only IDS will be unblinded as to 
the contents of each bottle of investigational product.  
Parent(s)/guardian(s) will be given detailed written dosing and storage instructions. 

IDDRC PILI/Lovastatin  
DOS 5.1 (Version Date: 07-Nov-2017) 
Page 28 
For IRB Use 
Document Revision Date: July 12, 2013 
 
 
All financial interests have been disclosed. No conflicts of interest have been 
identified for this study. The investigator will act in compliance with the study 
protocol and FDA regulations as stipulated in 21 CFR 312. 
Lovastatin is an FDA-approved medication for hyperlipidemia and has an established 
adverse events profile explained in the package insert. 
We have utilized lovastatin clinically in five children with FXS and seen a response 
in enhanced language in all of them. For instance, the mother of an 11-year-old old 
boy with autism and FXS who was started on lovastatin (20mg a day) stated that he 
“came out of the fog” and he started verbalizing more by utilizing new phrases for the 
first time and “using more combinations of new words”. His eye contact improved, 
as did his overall behavior. Although his mother stated that he is still “spinning 
things”, she adds that “he is now using pretend play which is new for him”. There 
were no side effects and his cholesterol and other laboratory studies remained 
normal. These data and the considerable safety and efficacy data for treating 
cognitive impairments in NF1 (Acosta, 2011) suggest a controlled trial in FXS is 
warranted. 
 
 
Applicable to: 
FDA Regulation 
I
N
D
  
I
D
E 
Abbre
viated 
IDE 
studies 
21 CFR 11 
• Electronic Records and Signatures 
X 
X 
 
21 CFR 54 
• Financial Disclosure by Clinical 
Investigators 
X 
X 
 
21 CFR 210 
• Current Good Manufacturing Practice in 
Manufacturing, Processing, Packing, or 
Holding of Drugs 
X 
 
 
21 CFR 211 
• Current Good Manufacturing Practice for 
Finished Pharmaceuticals 
X 
 
 
21 CFR 312 
• Investigational New Drug Application 
X 
 
 
21 CFR 812 
• Investigational Device Exemptions 
 
X 
X 
21 CFR 820 
• Quality System Regulation 
 
X